- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07726654
The Longitudinal Cohort of Cerebral Small Vessel Disease in Ruijin Hospital
The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are:
- How does neurovascular coupling change during the progression of CSVD?
- How is the pattern/mapping of alterations in CSVD biomarkers? Participants will be observed and visit the research center annually to perform multi-modal MRI, PET, neuropsychological tests, and blood tests.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
This observational study recruits participants with cerebral small vessel disease (CSVD) from hospitals and community-based populations. Healthy volunteers will also be recruited as controls. Longitudinal follow-up of these participants will help clarify the significance of neuroimaging and biological biomarkers during the development and progression of CSVD.
The investigators aim to establish a longitudinal cohort covering the spectrum of CSVD and identify key biomarkers associated with disease progression and cognitive decline. All participants will undergo multimodal MRI, PET imaging (optional) with different tracers, and blood biomarker assessments. Using multimodal MRI, the investigators will investigate alterations in neurovascular coupling and their role in the pathophysiology of CSVD. In addition, PET imaging (optional) and blood biomarkers will be used to characterize the spatial and temporal patterns of disease-related biomarker changes. Furthermore, additional neuroimaging and digital biomarkers will be evaluated within the cohort to improve disease characterization and prognostic prediction.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kiina, 200025
- Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
Ottaa yhteyttä:
- Jingyan Tian, Dr
- Puhelinnumero: 13671865057
- Sähköposti: tjy11488@rjh.com.cn
-
Päätutkija:
- Jingwen Jiang, Dr.
-
Alatutkija:
- Binyin Li, Dr.
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Age ≥18 years.
Evidence of cerebral small vessel disease (CSVD) on brain MRI, meeting at least one of the following imaging criteria:
- White matter hyperintensities (WMH) with a total Fazekas score ≥2;
- Fazekas score =1 with at least two vascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoking, or a history of vascular events other than stroke);
- Fazekas score =1 accompanied by the presence of lacunes;
- Imaging evidence of a recent subcortical lacunar infarction.
- Independent in activities of daily living (modified Rankin Scale [mRS] ≤2).
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Acute ischemic stroke with a diffusion-weighted imaging (DWI) lesion >20 mm in diameter.
- Acute intracerebral hemorrhage.
- Acute subarachnoid hemorrhage, a history of aneurysmal subarachnoid hemorrhage or cerebrovascular malformation, or the presence of an untreated intracranial aneurysm >3 mm in diameter.
- Previously diagnosed neurodegenerative disorders, such as Alzheimer's disease (AD) or Parkinson's disease (PD).
- Definite non-vascular white matter diseases, including multiple sclerosis, adult-onset leukodystrophy, metabolic encephalopathy, or other non-vascular white matter disorders.
- Major psychiatric disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- Contraindications to MRI (e.g., severe claustrophobia or MRI-incompatible implants).
- Severe systemic diseases (e.g., active malignancy) with an expected life expectancy of less than 5 years.
- Inability to complete scheduled follow-up because of geographic, logistical, or other reasons.
- Concurrent participation in another interventional clinical trial.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Cognitively Normal
Participants do not have cognitive impairment.
|
|
Cerebral small vessel disease without dementia
Participants have vascular cognitive impairment, but no cognitive impairment
|
|
Vascular Dementia (VaD)
Participants have vascular cognitive impairment or difficulty in daily activity.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Global cognitive ability
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Mini-mental state examination
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Executive function
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Clock drawing test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Visual memory
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Rey-Osterich complex figure test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Short-term memory
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Auditory verbal learning test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Executive memory
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Symbol-digit test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Spatial executive function
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Trail making test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Naming ability
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Boston naming test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Language ability
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Language fluency test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Sleep quality
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Sleep disorder
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Movement ability
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Part III of the Unified Parkinson's Disease Rating Scale
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Brain volume
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Annual changes of volumes of brain
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Connectivity integrity of the neural circuit
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Annual changes of hippocampus related neural connectivity
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Volume of white matter lesions
Aikaikkuna: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Structural and functional MRI measures, including arterial spin labeling (ASL), diffusion MRI (dMRI), susceptibility-weighted imaging (SWI) and fluid-attenuated inversion recovery (FLAIR).
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- RJNeuroBank-SVD
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .